Expression Of Clusterin And GRP78 In Glioma And Its Relationship With Clinical Pathological Features

Backgroud: As the most common malignant tumor in central nervous system, Glioma, with an invasive growth pattern and high recurrence rate, was difficult to be completely cured by surgery. And the five-year survival rate was unsatisfactory. So glioma had been the focus and aporia in neurosurgical therapy for years. Apoptosis as a pivotal factor in arising and development of tumor had been paid more and more attention by neurologist and oncologist. As anti-apoptotis factors, Clusterin and GRP78 had been demonstrated highly expressed in a number of tumors. It's unclear whether Clusterin and GRP78 expressed in glioma.Objective:To study the expression of Clusterin and GRP78 in glioma and its relationship with clinical pathological features.Methods: The clinical material of 70 cases (38 were men and 32 were women with a mean age of 45.7 years, range(11-72)) of glioma who were first-diagnosis and treating in neurosurgery department of the affiliated hospital of North Sichuan Medical College during January 2007 and May 2010 were retrospectively analysed. All these patients haven't accepted radiotherapy or chemo-treatment before. According to the World Health Organization (WHO) grade of glioma, there was grade I in 15 Cases, II in 18 Cases, III in 17 Cases and IV in 20 Cases. These cases were divided into two groups: the low-grade glioma (WHO I-II) and the high-grade glioma(WHO III-IV). 10 pathological specimens resected in decompreesive craniectomy for patients (6 were men and 4 were women with a mean age of 35.5 years, range (18-59)) with traumatic brain injury were detected as control group. Written informed content was obtained from one direct relative of each patient that participated in the trial. The amount of positive cell in each specimen was evaluated by two independent pathologists who were masked to group allocation. The pathological specimens of these cases were detected for the expression of Clusterin and GRP78 with immunohistochemistry SP method. Statistical analysis was carried out by using SPSS 13.0. A Chisquare test and a Spearman test were carried out as appropriate. Statistical significance was taken as P-value<0.05.Results:1. The positive rate of Clusterin was 57% in pathological slices with glioma, there was obviously difference compared with control group (10%)(P<0.05). The expression of Clusterin in low-grade glioma (WHO I-II) (36%)was lower than in high-grade glioma(WHO III-IV)(76%)(P<0.05). There were no relationship between the expression of Clusterin and sex,age,tumor size.2. The positive rate of GRP78 was 51% in pathological slice with glioma, there was obviously difference compared with control group (0%)(P<0.05). The expression of GRP78 in low-grade glioma (WHO I-II) (32%)was lower than in high-grade glioma(WHO III-IV)(70%)(P<0.05). There were no relationship between the expression of GRP78 and sex,age,tumor size.3. The number of GRP78(+) in 40 Clusterin(+) pathological slices with glioma was 30, and there were 24 cases of GRP78(-) in 30 Clusterin(-) pathological slices. Statistical analysis showed a positive correlative between the expression of Clusterin and GRP78 (rs=0.545, X2=20.76, P<0.05). Conclusions1. Clusterin expressed clearly in human glioma cells. Clusterin expressed more obviously in high-grade glioma than low-grade glioma. Clusterin might be an important element in arising and development in human glioma. There were no relationship between the expression of Clusterin and sex,age,tumor size.2. GRP78 expressed clearly in human glioma cells. GRP78 expressed more obviously in high-grade glioma than low-grade glioma. GRP78 might be an important element in arising and development of human glioma. There were no relationship between the expression of GRP78 and sex,age,tumor size.3. Taking full advantage of Clusterin and GRP78 together can suggest the degree of anti-apoptotic and predict the prognosis. It should be a new way to study the glioma.